课题基金 / 基金详情

Tak1, a novel prostate cancer tumor suppressor

Tak1, a novel prostate cancer tumor suppressor
Tak1,一种新型前列腺癌肿瘤抑制因子
批准号:
7828004
负责人:
Scott D Cramer
金额:
$30.71万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2014-04-30
关键词:
AffectAnimal ModelAnimalsApoptosisBMP4Cancer ModelCellsCellular biologyCharacteristicsChromosomesClinicalCrowdingCuesDNADataDiagnosisDifferentiation and GrowthDiseaseEpithelialEpithelial CellsEpitheliumFaceFamilyFibrous capsule of kidneyFreezingGene DeletionGene DosageGenesGeneticGenitourinary systemGleason Grade for Prostate CancerGrowthHeterozygoteHuman GenomeHyperplasiaIn VitroInterleukin-1Knockout MiceLeadLuciferasesLymph Node InvolvementMAP kinase kinase kinase 7MAP3K7 geneMalignant NeoplasmsMalignant neoplasm of prostateMediatingMesenchymalMethylationMissense MutationMitogen-Activated Protein KinasesModelingMutationNeoplasm MetastasisNormal tissue morphologyNuclear AtypiaNude MiceOncogenesPTEN genePathway interactionsPenetrationPhenotypePhosphotransferasesPopulation StudyPrevalencePrognostic MarkerProliferatingProliferation MarkerProstateProstatic Intraepithelial NeoplasiasProstatic NeoplasmsProtein-Serine-Threonine KinasesProteinsRadical ProstatectomyRecombinantsRoleSamplingSeminal VesiclesSerineSignal TransductionSignal Transduction PathwaySignaling MoleculeStem cellsStromal CellsTNF geneTestingTimeTissue GraftsTissue RecombinationTissuesTumor Suppressor GenesTumor Suppressor ProteinsUniversitiesWeightcohortdensityfetalforestgene interactionhuman MAP3K7 proteinin vivointerdisciplinary approachmalemedical schoolsmembermenmonolayermouse modelneoplastic cellnovelnovel strategiesoverexpressionprogenitorpromoterpublic health relevanceresponsestem cell differentiationtherapeutic targettumortumor progressiontumorigenesis

项目摘要

项目成果

Scott D Cramer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): TGF beta-activated kinase 1 (Tak1) is a serine-theonine kinase encoded by the MAP3K7 gene. Tak1, a member of the MAP kinase family, was originally identified as a downstream target of non-canonical (non-Smad) TGF-? signaling, but is now known to be a central signaling molecule for a number of intracellular signal transduction pathways, including the interleukin 1, TNF, Toll, and Wnt/?-catenin pathways. As such it is considered an important regulatory molecule that integrates multiple pathways involved in growth and differentiation. Little is known about the role of Tak1 in the normal prostate or in prostate cancer. We recently demonstrated deletion of the Tak1 locus in approximately 38% of primary prostate tumors. The prevalence of Tak1 deletion was equivalent to the prevalence of PTEN deletions in the same study population. There was significant association between loss of Tak1 and high Gleason score. Preliminary data support a role for loss of Tak1 in prostate tumorigenesis. Because of these preliminary data and the known role of Tak1 as a key integrator of multiple signals from the microenvironment, we propose the hypothesis that Tak 1 is a tumor suppresser for prostate cancer and that Tak1 functions to regulate growth and or differentiation of prostate epithelial cells in response to the microenvironment. We will test this hypothesis with a multidisciplinary approach that combines high throughput genetics with cell biology and animal model studies. Three aims are proposed. Aim 1) Association of Tak1 deletion with Gleason Grade; Aim 2) Prostate-Specific Deletion of Tak1 In Vivo; Aim 3) The role of the tumor microenvironment in Tak1 deficiency. If our hypothesis is correct these studies are significant because they will: 1) Determine the association of Tak1 deletion with prostate tumor progression prognostic markers 2) Identify Tak1 as a prostate tumor suppressor 3) Determine the role of Tak1 in the context of the tumor microenvironment. Identification of the role of Tak1 in prostate tumorigenesis and potential gene-gene interactions are also important because they may lead to novel strategies for prostate cancer therapeutic targeting. PUBLIC HEALTH RELEVANCE: Prostate cancer is a deadly disease that affects one in six men in the US. We have identified a potential prostate cancer tumor suppressor gene located on chromosome 6q15, the MAP3K7 gene. Our studies will test if this gene is a prostate cancer tumor suppressor and interrogate its downstream targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Androgen Signaling in CaP with loss of MAP3K7 and CHD1
  • 批准号:
    10657393
  • 项目类别:
  • 资助金额:
    $38.41万
  • 财政年份:
    2021
  • 负责人:
    Scott D Cramer
  • 依托单位:
Androgen Signaling in CaP with loss of MAP3K7 and CHD1
  • 批准号:
    10276486
  • 项目类别:
  • 资助金额:
    $39.19万
  • 财政年份:
    2021
  • 负责人:
    Scott D Cramer
  • 依托单位:
Androgen Signaling in CaP with loss of MAP3K7 and CHD1
  • 批准号:
    10439892
  • 项目类别:
  • 资助金额:
    $38.41万
  • 财政年份:
    2021
  • 负责人:
    Scott D Cramer
  • 依托单位:
Training Program in Cancer Biology
  • 批准号:
    10332080
  • 项目类别:
  • 资助金额:
    $25.18万
  • 财政年份:
    2016
  • 负责人:
    Scott D Cramer
  • 依托单位:
海外基金